BE805505A - Rapamycine et procede pour la preparer - Google Patents

Rapamycine et procede pour la preparer

Info

Publication number
BE805505A
BE805505A BE136212A BE136212A BE805505A BE 805505 A BE805505 A BE 805505A BE 136212 A BE136212 A BE 136212A BE 136212 A BE136212 A BE 136212A BE 805505 A BE805505 A BE 805505A
Authority
BE
Belgium
Prior art keywords
rapamycin
preparing
Prior art date
Application number
BE136212A
Other languages
English (en)
Inventor
S N Sehgal
T M Blazekovic
C Vezina
Original Assignee
Ayerst Mckenna & Harrison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayerst Mckenna & Harrison filed Critical Ayerst Mckenna & Harrison
Publication of BE805505A publication Critical patent/BE805505A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
BE136212A 1972-09-29 1973-09-28 Rapamycine et procede pour la preparer BE805505A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29369972A 1972-09-29 1972-09-29

Publications (1)

Publication Number Publication Date
BE805505A true BE805505A (fr) 1974-03-28

Family

ID=23130177

Family Applications (1)

Application Number Title Priority Date Filing Date
BE136212A BE805505A (fr) 1972-09-29 1973-09-28 Rapamycine et procede pour la preparer

Country Status (21)

Country Link
US (1) US3929992A (fr)
AR (1) AR197832A1 (fr)
AU (1) AU474405B2 (fr)
BE (1) BE805505A (fr)
CA (1) CA1000631A (fr)
CH (1) CH591558A5 (fr)
CS (1) CS185630B2 (fr)
DD (1) DD107070A5 (fr)
DE (1) DE2347682C2 (fr)
DK (1) DK134607B (fr)
ES (1) ES419160A1 (fr)
FR (1) FR2201076B1 (fr)
GB (1) GB1436447A (fr)
HK (1) HK51079A (fr)
HU (1) HU166346B (fr)
IE (1) IE38267B1 (fr)
IN (1) IN139114B (fr)
NL (1) NL175641C (fr)
SE (1) SE399437B (fr)
YU (1) YU37358B (fr)
ZA (1) ZA737247B (fr)

Families Citing this family (397)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069316A (en) * 1976-11-01 1978-01-17 Takeda Chemical Industries, Ltd. Method for producing antibiotic T-42082 and antibiotic T-42082
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4230692A (en) * 1978-11-03 1980-10-28 Ayerst Mckenna & Harrison, Inc. Ravidomycin and process of preparation
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) * 1981-11-19 1983-03-01 Ayerst, Mckenna & Harrison Inc. Antibiotic AY24,668 and process of preparation
AR240943A1 (es) * 1985-02-05 1991-03-27 Sankio Company Limited Nuevo compuesto agroquimico denominado "sustancia n*51262" procedimiento para prepararlo y composicion que lo comprende"
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5120726A (en) * 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ES2089723T3 (es) 1992-03-27 1996-10-01 American Home Prod 29-demetoxirapamicina para inducir la inmunodepresion.
EP0633783B1 (fr) * 1992-03-30 2000-06-07 American Home Products Corporation Formulation de rapamycine pour injections intraveineuses
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (fr) * 1992-09-24 1994-03-25 Ralph J. Russo La 21-norrapamycine
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
GB9302569D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
EP1181938B1 (fr) 1993-04-23 2007-11-14 Wyeth Conjugués de Rapamycine et anticorps
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
EP0729471A1 (fr) * 1993-11-19 1996-09-04 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
WO1996006847A1 (fr) * 1994-08-31 1996-03-07 Pfizer Inc. Procede de preparation des demethylrapamycines
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5606222A (en) * 1994-12-29 1997-02-25 Philips Electronics North America Corporation Lighting system with a device for reducing system wattage
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US7282220B1 (en) 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
KR20010031363A (ko) * 1997-10-22 2001-04-16 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7419678B2 (en) * 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
WO2002026139A1 (fr) 2000-09-29 2002-04-04 Cordis Corporation Dispositifs medicaux enrobes
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (fr) 2001-08-22 2005-10-05 Wyeth 29-enols de la rapamycine
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) * 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US20070083258A1 (en) 2005-10-06 2007-04-12 Robert Falotico Intraluminal device and therapeutic agent combination for treating aneurysmal disease
ES2544624T3 (es) 2002-07-16 2015-09-02 Buck Institute For Research On Aging Producción de policétidos
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
CN100349627C (zh) 2002-09-06 2007-11-21 艾博特公司 含有水合抑制剂的医疗装置及其制备方法
AU2002330737A1 (en) * 2002-09-09 2004-03-29 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
UA81265C2 (en) * 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
US20050038504A1 (en) * 2003-01-22 2005-02-17 Harry Halleriet Kit for applying drug coating to a medical device in surgeon room
US6919100B2 (en) * 2003-01-22 2005-07-19 Cordis Corporation Method for coating medical devices
US8318235B2 (en) * 2003-01-22 2012-11-27 Cordis Corporation Method for applying drug coating to a medical device in surgeon room
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20040167572A1 (en) * 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7527632B2 (en) * 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
WO2004100868A2 (fr) * 2003-04-23 2004-11-25 Abbott Laboratories Procede servant a traiter le rejet d'un transplant
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20040236416A1 (en) * 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US20050137677A1 (en) * 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
US20050249776A1 (en) * 2003-12-19 2005-11-10 Chen Chao C Coated aneurysmal repair device
US8747881B2 (en) 2003-12-19 2014-06-10 Cordis Corporation Intraluminal medical devices in combination with therapeutic agents
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
DE602004011398T2 (de) * 2004-01-08 2009-01-15 Wyeth Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US7806924B2 (en) 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
EP1568394A1 (fr) 2004-02-26 2005-08-31 Muijs van de Moer, Wouter Matthijs Electrode à revêtement
US8828416B2 (en) 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
EP2301619B1 (fr) * 2004-03-19 2017-05-10 Abbott Laboratories Administration de médicaments multiples à partir d'un ballonnet et d'une prothèse
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7875282B2 (en) * 2004-03-22 2011-01-25 Cordis Corporation Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
EP1756290B1 (fr) * 2004-04-12 2016-05-04 Biocon Limited Streptomyces espece bicc 7522 et son utilisation pour la production de macrolides
PL1735321T3 (pl) 2004-04-14 2009-04-30 Wyeth Corp Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
US8007737B2 (en) 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
KR20070015544A (ko) 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성
EP1751168A1 (fr) 2004-04-14 2007-02-14 Wyeth Proline cci-779 (ester de proline-rapamycine 42 avec acide propionique de 2,2-bis (hydroxymethyle) et synthese enzymatique en deux etapes de proline cci-779 et cci-779 par lipase microbienne
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
CN1946852A (zh) * 2004-04-27 2007-04-11 惠氏公司 利用雷帕霉素特异性甲基化酶标记雷帕霉素
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
AR050374A1 (es) * 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
CA2578245C (fr) * 2004-08-27 2013-10-29 Cardinal Health 529, Llc Rapamycine amorphe exempte de solvant
JP2008512125A (ja) * 2004-09-10 2008-04-24 アイバックス ファーマシューティカルズ スポレツノスト エス ルチェニム オメゼニム マクロリド化合物を単離する方法
MX2007002808A (es) * 2004-09-10 2007-10-10 Ivax Pharmaceuticals Sro Proceso para el aislamiento de tacrolimus cristalino.
AU2005284422A1 (en) * 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2006039237A1 (fr) * 2004-09-29 2006-04-13 Cordis Corporation Formes posologiques pharmaceutiques de composes amorphes stables semblables a la rapamycine
US20060129225A1 (en) * 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
JP5242374B2 (ja) 2005-03-23 2013-07-24 アボット・ラボラトリーズ 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
EP2327429B1 (fr) 2005-03-23 2014-09-17 Abbott Laboratories Administration d'agents lipophiles par dispositifs médicaux
KR101492545B1 (ko) * 2005-07-15 2015-02-12 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
WO2007011708A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent a revetement polymere renfermant de la rapamycine amorphe
ES2691646T3 (es) * 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US20070048350A1 (en) 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US20090246212A1 (en) * 2005-09-30 2009-10-01 Kyoto University Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US20070128242A1 (en) * 2005-12-01 2007-06-07 Zhao Jonathan Z Polymeric compositions for controlled release or delivery of pharmacologically active agents
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US7842312B2 (en) * 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
CA2996768C (fr) 2006-04-26 2020-12-08 Micell Technologies, Inc. Revetements contenant plusieurs medicaments
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
EP2040758A4 (fr) * 2006-06-30 2014-09-17 Interface Biologics Inc Polymeres biosensibles
US8506984B2 (en) 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
WO2008022256A2 (fr) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
WO2008042909A2 (fr) 2006-10-02 2008-04-10 Micell Technologies Inc. Sutures chirurgicales ayant une résistance accrue
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
JP5336382B2 (ja) 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP1938800A1 (fr) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Nanodispersion de sirolimus
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP1952807A1 (fr) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Formulation de Sirolimus
US20090281059A1 (en) * 2007-02-21 2009-11-12 Robert Falotico Coating for a medical device having an anti-thrombotic conjugate
US20080241215A1 (en) 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
CN101815540B (zh) 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US20090068266A1 (en) * 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
JP5599712B2 (ja) 2007-10-05 2014-10-01 インターフェース バイオロジクス，インコーポレーテッド オリゴフッ素化架橋ポリマーおよびそれの使用
ES2623456T3 (es) 2007-10-19 2017-07-11 Interface Biologics Inc. Recubrimientos autoeliminantes
AU2008318678B2 (en) * 2007-10-31 2014-02-13 Cardinal Health 529, Llc Vascular closure device
US9603980B2 (en) 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2721832C (fr) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents a couches bioabsorbables
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
AU2009257602B2 (en) 2008-06-10 2015-10-08 Abbvie Inc. Novel tricyclic compounds
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010009335A1 (fr) 2008-07-17 2010-01-21 Micell Technologies, Inc. Dispositif médical d’administration de médicament
EP2352459A4 (fr) * 2008-10-03 2013-09-25 Elixir Medical Corp Composés lactones macrocycliques et leurs méthodes d'utilisation
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
CA2937492C (fr) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition de cible mammalienne de rapamycine
AR074897A1 (es) * 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2011006890A (es) * 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20120231037A1 (en) * 2009-02-02 2012-09-13 Yissum Research Development Companyof the Hebrew U Crystalline drug-containing coatings
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
WO2010118419A2 (fr) 2009-04-10 2010-10-14 Haiyan Qi Nouveaux agents anti-vieillissement et leurs procédés d'identification
EP3366326A1 (fr) 2009-04-17 2018-08-29 Micell Technologies, Inc. Endoprothèses vasculaires ayant une élution contrôlée
US20100268187A1 (en) * 2009-04-17 2010-10-21 Ranbaxy Laboratories Limited Packaging for sirolimus and composition thereof
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
US9327060B2 (en) * 2009-07-09 2016-05-03 CARDINAL HEALTH SWITZERLAND 515 GmbH Rapamycin reservoir eluting stent
US20110137407A1 (en) 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs
EP2453834A4 (fr) 2009-07-16 2014-04-16 Micell Technologies Inc Dispositif médical distributeur de médicament
PH12012500809A1 (en) 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
EP4782062A2 (fr) 2009-12-01 2026-07-29 AbbVie Inc. Nouveaux composés tricycliques
JP2013512282A (ja) * 2009-12-01 2013-04-11 アボット・ラボラトリーズ 新規三環式化合物
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
EP2531140B1 (fr) 2010-02-02 2017-11-01 Micell Technologies, Inc. Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
WO2011128910A2 (fr) 2010-03-02 2011-10-20 Rpg Life Sciences Limited Formulation pharmaceutique solide pour administration médicamenteuse à base de sirolimus
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
WO2011133655A1 (fr) 2010-04-22 2011-10-27 Micell Technologies, Inc. Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire
WO2012009684A2 (fr) 2010-07-16 2012-01-19 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US20120130481A1 (en) 2010-11-18 2012-05-24 Robert Falotico Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
WO2012166819A1 (fr) 2011-05-31 2012-12-06 Micell Technologies, Inc. Système et procédé de formation de revêtement transférable à élution de médicament, libéré dans le temps
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN102372726B (zh) * 2011-11-08 2014-02-19 福建省微生物研究所 西罗莫司粗晶的制备方法
CN102433364B (zh) * 2011-11-10 2013-10-23 中科医药行业生产力促进中心有限公司 一种微生物发酵法制取雷帕霉素的工艺
EP2594260A1 (fr) 2011-11-18 2013-05-22 LEK Pharmaceuticals d.d. Préparations solides comportant du sirolimus avec la biodisponibilité souhaitée et leur procédé de préparation
AU2012351728A1 (en) 2011-12-16 2014-06-19 Oncology Institute Of Southern Switzerland Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2013153554A1 (fr) 2012-04-12 2013-10-17 Natco Pharma Limited Procédé de fermentation pour la production de rapamycine
CN104203959B (zh) 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
US9278090B2 (en) 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders
WO2014068070A1 (fr) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour prévenir le syndrome des antiphospholipides (sapl)
WO2014072984A1 (fr) 2012-11-06 2014-05-15 Natco Pharma Limited Processus amélioré d'isolation et de purification de rapamycine à partir d'un bouillon de fermentation
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
WO2014186532A1 (fr) 2013-05-15 2014-11-20 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
RU2016136348A (ru) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015142661A1 (fr) 2014-03-15 2015-09-24 Novartis Ag Récepteur d'antigène chimèrique régulable
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
WO2016019300A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Sous-ensemble optimisé de lymphocytes t contenant un récepteur d'antigène chimère
EP3180359A1 (fr) 2014-08-14 2017-06-21 Novartis AG Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4
EP3712171A1 (fr) 2014-08-19 2020-09-23 Novartis AG Traitement du cancer à l'aide d'un récepteur d'antigène chimérique cd123
EP3193902A4 (fr) 2014-09-11 2018-03-28 The Regents of The University of California Inhibiteurs de mtorc1
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2963085C (fr) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. Formulation de rapamycine inhalable pour le traitement de l'hypertension pulmonaire
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3473253A1 (fr) 2014-10-29 2019-04-24 University Of Maryland Procédés de traitement des symptômes liés à l'âge chez les mammifères et compositions à cet effet
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016098078A2 (fr) 2014-12-19 2016-06-23 Novartis Ag Commutateurs de dimérisation et leurs utilisations
WO2016130645A1 (fr) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycine destinée au traitement de la lymphangioléiomyomatose
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN104844620B (zh) * 2015-04-10 2018-06-19 鲁南新时代生物技术有限公司 一种雷帕霉素的分离纯化方法
WO2016168595A1 (fr) 2015-04-17 2016-10-20 Barrett David Maxwell Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique
WO2016172583A1 (fr) 2015-04-23 2016-10-27 Novartis Ag Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017029391A1 (fr) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de traitement du cancer
US20180258100A1 (en) * 2015-08-28 2018-09-13 Matthew Alan Gregory RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11357851B2 (en) 2015-11-11 2022-06-14 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
JP2020500930A (ja) 2016-11-23 2020-01-16 ノバルティス アーゲー エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法
CN110603038A (zh) 2017-02-10 2019-12-20 塔姆山治疗公司 雷帕霉素类似物
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3644997A1 (fr) 2017-06-26 2020-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
WO2019157516A1 (fr) 2018-02-12 2019-08-15 resTORbio, Inc. Polythérapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (fr) 2018-05-01 2024-08-28 Revolution Medicines, Inc. Analogues de rapamycine liés à c26 utilisés en tant qu'inhibiteurs de mtor
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3826649A4 (fr) 2018-07-23 2022-07-20 Enclear Therapies, Inc. Méthodes de traitement de troubles neurologiques
EP3849545A1 (fr) 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés de traitement de la neurofibromatose
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
US12594275B2 (en) 2019-02-07 2026-04-07 The Regents Of The University Of California Immunophilin binding agents and uses thereof
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
CA3149796A1 (fr) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Agents anticancereux pour le traitement des cancers canins
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム
AU2020277132B1 (en) 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer
EP4531859A4 (fr) 2022-05-25 2026-05-27 Revolution Medicines Inc Méthodes de traitement du cancer au moyen d'un inhibiteur de mtor
WO2024008799A1 (fr) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Méthodes de traitement de la glomérulonéphrite proliférative
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024211738A1 (fr) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Analogues de rapamycine sélectifs et leurs utilisations

Also Published As

Publication number Publication date
HK51079A (en) 1979-08-03
YU37358B (en) 1984-08-31
DD107070A5 (fr) 1974-07-12
DK134607C (fr) 1977-05-16
GB1436447A (en) 1976-05-19
FR2201076A1 (fr) 1974-04-26
DE2347682C2 (de) 1984-08-02
NL175641B (nl) 1984-07-02
HU166346B (fr) 1975-03-28
NL175641C (nl) 1984-12-03
IE38267L (en) 1974-03-29
IN139114B (fr) 1976-05-08
CH591558A5 (fr) 1977-09-30
CS185630B2 (en) 1978-10-31
NL7313386A (fr) 1974-04-02
DE2347682A1 (de) 1974-04-11
IE38267B1 (en) 1978-02-01
ES419160A1 (es) 1976-06-16
AU474405B2 (en) 1976-07-22
FR2201076B1 (fr) 1977-09-09
SE399437B (sv) 1978-02-13
AR197832A1 (es) 1974-05-10
US3929992A (en) 1975-12-30
ZA737247B (en) 1975-04-30
CA1000631A (en) 1976-11-30
DK134607B (da) 1976-12-06
YU246473A (en) 1983-04-27
AU6044773A (en) 1975-03-20

Similar Documents

Publication Publication Date Title
AU476649B2 (en) Apparatus for molding articles
FR2296616A1 (fr) Nouvelles acyldiamines et procede pour leur obtention
BE807283A (fr) Granules de polyester et procede pour les preparer
BE797414A (fr) Nouvelles amines et procede pour leur preparation
BE808599A (fr) Nouvelles pyrazolodiazepines et procede pour les preparer
BE799139A (fr) Derives antibiotiques et procede pour les preparer
BE799742A (fr) Esters sulfonato-benzylmaloniques et procede de preparation,
BE804350A (fr) Agents antibacteriens et procede pour les preparer
BE794532A (fr) Nouvelles 3-hydroxymethyl-5-benzylidene-azolidinones et procede pour les fabriquer
BE791904A (fr) Procede de deshydrochloration
BE808316A (fr) Procede pour la preparation de beta-alcoxy-omega-lactames
RO65173A (fr) Procede d'obtenir le complex d'antibiotiques a25822
BE804251A (fr) Agents antibacteriens et procede pour les preparer
BE800635A (fr) Agents antibacteriens et procede pour les preparer
BE807347A (fr) Phenylpyridazines et procede pour leur preparation
BE754693A (fr) Nouvel antibiotique et procede pour le preparer
BE806277A (fr) Procede pour la preparation de cycloalcanones et de cycloalcanols
RO64170A (fr) Procede pour obtenir l'antibiotique a-2315
BE799098A (fr) Derives de pyrazole et procede pour les preparer
RO65788A (fr) Procede pour obtenir des penicilines procede pour obtenir des penicillines
RO62772A (fr) Procede pour obtenir des oximcarbamates n-sulfeniles
BE804615A (fr) Nouveau procede de reduction
FR2282865A2 (fr) Procede pour preparer de nouvelles substances antibiotiques
BE750096A (fr) Nouvel antibiotique appele negamycine et procede pour le preparer
BE794066A (fr) Procede de preparation de 2-mercapto-benzimidazol

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: AYERST MCKENNA & HARRISON LTD

Effective date: 19930928